(Total Views: 604)
Posted On: 12/16/2021 12:17:05 PM
Post# of 155764
Ohm 20, this is great news!
My hope always was and Cytodyn has this done this year, that we expand the team with scientifically and technically competent employees, because we have to recognize that success can only be achieved through positive clinical trials that meet scientific standards and through further in-depth studies on the role of the CCR 5 receptor and the mode of action of Leronlimab in different clinical pictures. If you take your (Ohm20's) list of diseases that could potentially be treatable with Leronlimab, you can see how much scientific groundwork is still ahead of our company.
In this context, one of the positive developments this year is the systematic scientific approach of Dr. Recknor on various problems, another the cooperation with the Albert Einstein Israelite Hospital in Brazil or the clinic in Texas. I would like to see some input from the members of the scientific advisory board.
My hope always was and Cytodyn has this done this year, that we expand the team with scientifically and technically competent employees, because we have to recognize that success can only be achieved through positive clinical trials that meet scientific standards and through further in-depth studies on the role of the CCR 5 receptor and the mode of action of Leronlimab in different clinical pictures. If you take your (Ohm20's) list of diseases that could potentially be treatable with Leronlimab, you can see how much scientific groundwork is still ahead of our company.
In this context, one of the positive developments this year is the systematic scientific approach of Dr. Recknor on various problems, another the cooperation with the Albert Einstein Israelite Hospital in Brazil or the clinic in Texas. I would like to see some input from the members of the scientific advisory board.
(2)
(0)
